Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
antibiotic-resistant bacteria
Biotech
ContraFect halts phase 3 after antimicrobial fails futility test
The inability of the direct lytic agent to beat placebo triggered the stoppage of the study and the cratering of the biotech’s share price.
Nick Paul Taylor
Jul 14, 2022 10:35am
Stopping DNA 'packet' exchange could halt bacterial resistance
Jun 14, 2022 8:30am
Lack of policy, investment stifling antibiotics pipeline
Apr 12, 2022 9:00am
Big Pharma-backed AMR Action Fund picks 1st biotech investments
Apr 4, 2022 10:25am
BD joins Day Zero's $21M funding for genomics-based diagnostics
Feb 10, 2022 11:26am
Entasis antibiotic beats last resort treatment in phase 3 trial
Oct 19, 2021 10:35am
